Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11555193 | 0.91 | CHRM5 (0.33) | CHRM5ADRA2C | |
| SCHEMBL945748 | 0.89 | CHRM5 (0.36) | CHRM5ADRA2CHRH3 | |
| SCHEMBL947318 | 0.81 | CXCR4 (0.40) | CXCR4HRH3 | |
| SCHEMBL2289712 | 0.79 | CXCR4 (0.31) | CXCR4 | |
| SCHEMBL5157997 | 0.75 | GAA (0.31) | — | |
| SCHEMBL39245 | 0.74 | CHRM5 (0.43) | CHRM5ADRA2C | |
| SCHEMBL713122 | 0.74 | CHRM5 (0.43) | CHRM5ADRA2C | |
| SCHEMBL947556 | 0.73 | CXCR4 (0.39) | CXCR4HRH3 | |
| SCHEMBL2439970 | 0.72 | CHRM5 (0.46) | CHRM5ADRA2CHRH3 | |
| SCHEMBL945327 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1521751-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | Astrazeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005284-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | CHRM5 1029/4885ADRA2C 1053/4885CXCR4 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.